Cerebral near infrared spectroscopy oximetry in extremely preterm infants: phase II randomised clinical trial

BMJ. 2015 Jan 5;350:g7635. doi: 10.1136/bmj.g7635.

Abstract

Objective: To determine if it is possible to stabilise the cerebral oxygenation of extremely preterm infants monitored by cerebral near infrared spectroscopy (NIRS) oximetry.

Design: Phase II randomised, single blinded, parallel clinical trial.

Setting: Eight tertiary neonatal intensive care units in eight European countries.

Participants: 166 extremely preterm infants born before 28 weeks of gestation: 86 were randomised to cerebral NIRS monitoring and 80 to blinded NIRS monitoring. The only exclusion criterion was a decision not to provide life support.

Interventions: Monitoring of cerebral oxygenation using NIRS in combination with a dedicated treatment guideline during the first 72 hours of life (experimental) compared with blinded NIRS oxygenation monitoring with standard care (control).

Main outcome measures: The primary outcome measure was the time spent outside the target range of 55-85% for cerebral oxygenation multiplied by the mean absolute deviation, expressed in %hours (burden of hypoxia and hyperoxia). One hour with an oxygenation of 50% gives 5%hours of hypoxia. Secondary outcomes were all cause mortality at term equivalent age and a brain injury score assessed by cerebral ultrasonography.

Randomisation: Allocation sequence 1:1 with block sizes 4 and 6 in random order concealed for the investigators. The allocation was stratified for gestational age (<26 weeks or ≥ 26 weeks).

Blinding: Cerebral oxygenation measurements were blinded in the control group. All outcome assessors were blinded to group allocation.

Results: The 86 infants randomised to the NIRS group had a median burden of hypoxia and hyperoxia of 36.1%hours (interquartile range 9.2-79.5%hours) compared with 81.3 (38.5-181.3) %hours in the control group, a reduction of 58% (95% confidence interval 35% to 73%, P<0.001). In the experimental group the median burden of hypoxia was 16.6 (interquartile range 5.4-68.1) %hours, compared with 53.6 (17.4-171.3) %hours in the control group (P=0.0012). The median burden of hyperoxia was similar between the groups: 1.2 (interquartile range 0.3-9.6) %hours in the experimental group compared with 1.1 (0.1-23.4) %hours in the control group (P=0.98). We found no statistically significant differences between the two groups at term corrected age. No severe adverse reactions were associated with the device.

Conclusions: Cerebral oxygenation was stabilised in extremely preterm infants using a dedicated treatment guideline in combination with cerebral NIRS monitoring.Trial registration ClinicalTrial.gov NCT01590316.

Publication types

  • Clinical Trial, Phase II
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brain / blood supply*
  • Cerebrovascular Circulation
  • Clinical Protocols
  • Europe
  • Guideline Adherence*
  • Humans
  • Hypoxia / diagnosis*
  • Hypoxia / pathology
  • Infant, Extremely Premature
  • Infant, Newborn
  • Intensive Care Units, Neonatal
  • Intensive Care, Neonatal*
  • Monitoring, Physiologic / methods*
  • Oximetry* / methods
  • Practice Guidelines as Topic
  • Spectroscopy, Near-Infrared* / methods
  • Time Factors
  • Treatment Outcome

Associated data

  • ClinicalTrials.gov/NCT01590316